We start 2018 with an issue dedicated entirely to oncology. We showcase a number of companies working in the field, focusing on areas such as immunotherapies, combination therapies, personalized medicine, diagnostics and biosimilars.
We also feature an editorial piece which covers recent trends in oncology dealmaking. With the help of Clarivate Analytics we explore the oncology licensing deals of the last 5 years analysing by company, value, volume and development stage.
Read the full issue here.